Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
VANCOUVER and MINNEAPOLIS – 
(NewMediaWire) – January 04, 2021 – Neovasc Inc.
(Nasdaq, TSX: NVCN), today announced its
participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which
takes place January 11-14, 2021. Neovasc President and Chief Executive
Officer Fred Colen, Chief Operating Officer Bill Little, and Chief Financial
Officer Chris Clark will be available for one-on-one investor meetings during
the event; meetings may be requested through H.C. Wainwright. Additionally, a webcast of Neovasc’s
recorded company presentation will be available on demand via the H.C.
Wainwright conference site beginning at 6:00 am ET on January 11, and on the
Neovasc website at https://www.neovasc.com/presos/
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for the rapidly
growing cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially available
in the United States and has been commercially available in Europe since 2015,
and Tiara, for the transcatheter treatment of mitral valve disease, which is
currently under clinical investigation in the United States, Canada, Israel and
Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
